Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0V9LJ
|
|||
Former ID |
DIB008719
|
|||
Drug Name |
Flufirvitide-3
|
|||
Indication | Influenza virus infection [ICD-11: 1E30-1E32] | Phase 1 | [1] | |
Company |
Autoimmune technologies
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C87H133N19O29
|
|||
Canonical SMILES |
CCC(C)C(C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CC(=O)N)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)N
|
|||
InChI |
1S/C87H133N19O29/c1-13-44(10)70(105-75(122)52(20-16-17-29-88)95-86(133)71(46(12)108)106-82(129)61(37-68(117)118)101-74(121)54(26-28-66(113)114)94-84(131)69(90)43(8)9)85(132)102-60(36-67(115)116)81(128)97-55(30-40(2)3)77(124)99-58(34-48-38-91-51-19-15-14-18-50(48)51)80(127)104-63(39-107)83(130)98-57(33-47-21-23-49(109)24-22-47)79(126)100-59(35-64(89)110)76(123)92-45(11)72(119)93-53(25-27-65(111)112)73(120)96-56(31-41(4)5)78(125)103-62(87(134)135)32-42(6)7/h14-15,18-19,21-24,38,40-46,52-63,69-71,91,107-109H,13,16-17,20,25-37,39,88,90H2,1-12H3,(H2,89,110)(H,92,123)(H,93,119)(H,94,131)(H,95,133)(H,96,120)(H,97,128)(H,98,130)(H,99,124)(H,100,126)(H,101,121)(H,102,132)(H,103,125)(H,104,127)(H,105,122)(H,106,129)(H,111,112)(H,113,114)(H,115,116)(H,117,118)(H,134,135)/t44-,45-,46+,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,69-,70-,71-/m0/s1
|
|||
InChIKey |
GIKLOXPFVONKJH-PJLATTGVSA-N
|
|||
CAS Number |
156953-42-3
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01313962) Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.